Deusa Cast discusses the importance of compounding pharmacy for personalized treatments
In a segment of Deusa Cast, director of Anfarmag explains why the compounding sector is essential to ensure personalized treatments and complement the pharmaceutical industry
Published on 02/09/2026
Marco Fiaschetti, executive director of Anfarmag, defends the compounding pharmacy as a pillar of public health and personalized treatments. | Reproduction Sechat
The compounding pharmacy plays an essential role in public health by ensuring personalized treatments that industrial production, based on scale, cannot meet. The topic was discussed in the episode of Deusa Cast, a podcast from Portal Sechat, which featured Marco Fiaschetti, executive director of Anfarmag (National Association of Compounding Pharmacists).
During the conversation, Fiaschetti emphasized that the pharmaceutical industry and Deusa Cast discuss the importance of compounding pharmacy for personalized treatments do not compete with each other, but perform complementary functions within the healthcare system. While industrialized medications are essential to serve large populations, compounding fills specific gaps, adjusting formulations, dosages, and pharmaceutical forms to the individual needs of patients.
“Thinking on an industrial scale, it would be unfeasible to produce every type of medication specification to serve all audiences. There would be no demand, not enough patients for that,” explained Fiaschetti.
Brazil as an international reference
Another central point of Deusa Cast's segment was Brazil's leadership in the compounding sector. According to the director of Anfarmag, Brazil is now a global reference in compounding pharmacy, both for the complexity of formulations and for the regulatory rigor imposed by health authorities.
“Compounding pharmacy in Brazil is a world reference. No compounding pharmacy in the world is as advanced as in Brazil, both in terms of regulatory requirements and the range of specialties and formulations that can be prepared,” he stated.
Impacts of restrictions on the sector
The conversation also addressed the risks of limiting the activities of compounding pharmacies, especially in newer and specific therapies, such as medicinal cannabis. For Fiaschetti, restricting the work of compounding pharmacists represents a setback, as it is these professionals who have the technical training and appropriate infrastructure to turn individual demands into safe and effective treatments.
“Industrial products have their importance and role, but it also needs to be ensured that specific needs of certain patients can be met,” he emphasized.
The discussion highlights that the compounding pharmacy is a strategic ally of public health, contributing to the democratization of access to personalized therapies and expanding care possibilities in contexts where standardization is not sufficient.
